Cannabis and Migraines: Prevention, Treatment, and What Studies Show

Body / Physical

10.4 → 4.6/month

A Pharmacotherapy study found medical cannabis cut migraine frequency from 10.4 to 4.6 attacks per month, though this was retrospective data and randomized trials are only now beginning.

Pharmacotherapy, 2016

Pharmacotherapy, 2016

View as image

Migraine is not just a bad headache. It is a complex neurological condition that affects more than one billion people worldwide, making it the third most prevalent illness on the planet. Migraine attacks involve pulsating head pain, often on one side, accompanied by nausea, light and sound sensitivity, and sometimes visual aura. Attacks can last 4 to 72 hours and produce significant disability. The World Health Organization ranks migraine among the top ten causes of years lived with disability globally.

Despite advances in migraine treatment, including CGRP inhibitors, gepants, and ditans, many patients remain inadequately treated. Older preventive medications like topiramate, propranolol, and amitriptyline have significant side effects. Triptans are effective for many but do not work for everyone and carry cardiovascular contraindications. The reality is that migraine care still leaves a substantial number of patients looking for additional options. Cannabis is one of the options they are finding.

Endocannabinoid Deficiency and Migraines

Body / Physical

Cannabis & Migraines: Endocannabinoid Evidence

Anandamide Levels

Data: Lower in CSF of chronic migraine patients (Sarchielli 2007)

Implication: Supports endocannabinoid deficiency as migraine driver

Rhyne Study (2016)

Data: Migraine frequency dropped from 10.4 to 4.6/month with cannabis

Implication: 55% reduction — more than most preventive medications

Cuttler App Study (2020)

Data: Inhaled cannabis reduced severity by 49.6% in real-time tracking

Implication: Higher THC predicted greater relief; CBD content did not matter

CGRP Connection

Data: Endocannabinoids can inhibit CGRP release from trigeminal neurons

Implication: Same target as newest migraine drugs (CGRP inhibitors)

Medication Overuse Risk

Data: Unknown whether frequent cannabis use triggers rebound headaches

Implication: A real concern with all acute migraine treatments

Acute vs Preventive Use

Acute (stop attack)Inhaled — fast onset (minutes)Rebound headache risk unknown

Preventive (reduce frequency)Oral/sublingual — longer durationTolerance may reduce efficacy over time

Rhyne, Pharmacotherapy 2016 • Not medical adviceCannabis and Migraines Evidence

The theoretical connection between the endocannabinoid system and migraines is compelling. Neurologist Ethan Russo first proposed the Clinical Endocannabinoid Deficiency (CED) hypothesis in 2004, suggesting that conditions like migraine, fibromyalgia, and irritable bowel syndrome might share a common etiology of insufficient endocannabinoid system function.

Several lines of evidence support this hypothesis for migraines specifically.

Anandamide levels are reduced in the cerebrospinal fluid and blood of chronic migraine patients compared to healthy controls. Sarchielli and colleagues (2007) found significantly lower anandamide levels in the cerebrospinal fluid of chronic migraine sufferers, with levels correlating inversely with headache duration.

The endocannabinoid system modulates serotonergic, glutamatergic, and CGRP-mediated neurotransmission, all of which are central to migraine pathophysiology. CGRP (calcitonin gene-related peptide) is now recognized as a key mediator of migraine, and endocannabinoids can inhibit CGRP release from trigeminal neurons.

CB1 receptors are densely distributed in brain regions involved in migraine pathophysiology: the periaqueductal gray (PAG), thalamus, and trigeminal nucleus caudalis. Activation of CB1 in the PAG, a key pain modulation center, inhibits trigeminovascular nociception, the primary pain pathway in migraine.

Anandamide directly activates TRPV1 receptors, which are involved in trigeminal sensitization. The relationship is complex because TRPV1 activation can initially cause pain but repeated activation leads to desensitization, which may reduce migraine susceptibility.

Taken together, this evidence suggests that the endocannabinoid system is deeply integrated into migraine biology. If endocannabinoid tone is deficient in migraine patients, supplementing with exogenous cannabinoids has a logical rationale.

The Rhyne Study and Other Patient Data

The most cited study for cannabis and migraines is the retrospective chart review by Rhyne and colleagues, published in Pharmacotherapy in 2016. The study reviewed 121 adults with migraine who were recommended medical cannabis by a physician in Colorado.

The results were striking. Migraine frequency decreased from an average of 10.4 attacks per month to 4.6 attacks per month. Almost 40 percent of patients reported a positive effect overall. About 20 percent reported that cannabis helped abort acute migraine attacks. A smaller percentage reported negative effects, primarily drowsiness and difficulty controlling the dose with edibles.

This was not a randomized trial. It was a retrospective chart review with no control group, no blinding, and no standardized cannabis products. The patients were self-selected and highly motivated. Nevertheless, the magnitude of the frequency reduction, greater than 50 percent, is comparable to what successful preventive medications achieve in clinical trials.

A 2020 study by Cuttler and colleagues, published in the Journal of Pain, analyzed data from a cannabis tracking app (Strainprint) and found that inhaled cannabis reduced self-reported headache severity by 47.3 percent and migraine severity by 49.6 percent. The study also found that concentrates were more effective than flower, and that higher THC concentrations correlated with greater severity reduction. Notably, the study found no evidence of dose escalation over time for headache relief, though they did find reduced effectiveness over sessions, suggesting partial tolerance.

A 2021 prospective study by Aviram and Samuelly, published in Brain Sciences, followed 145 migraine patients using medical cannabis for three years. They found sustained reductions in migraine frequency and disability, decreased use of acute medications, and improved sleep quality.

Acute vs. Preventive Use

Cannabis may play different roles depending on whether it is used acutely (to treat an attack in progress) or preventively (to reduce attack frequency).

Acute use. For aborting or reducing the severity of a migraine attack, rapid onset is essential. Inhaled cannabis (smoked or vaporized) provides the fastest onset, typically within minutes. This timing is similar to triptans and better than oral medications. Some patients report that inhaling cannabis at the first sign of a migraine aura can prevent the attack from fully developing. Others report that it reduces the severity and duration of an established attack.

The challenge with acute use is dosing precision. Migraine attacks often come with nausea, making oral administration problematic. Inhalation provides rapid relief but makes it difficult to control the exact dose. Too much THC during a migraine can worsen nausea or produce disorienting psychoactive effects.

Preventive use. For reducing migraine frequency, consistent daily dosing with oral preparations may be more appropriate. Oral cannabis products provide slower onset but longer duration, typically 4 to 8 hours. A low-dose daily regimen could theoretically provide sustained modulation of the endocannabinoid system, addressing the hypothesized deficiency.

This approach has not been tested in clinical trials. The Rhyne study included patients using various delivery methods and schedules, and the frequency reduction was observed across the whole group. Whether a structured preventive dosing protocol would perform better than as-needed use is unknown.

THC vs. CBD for Migraines

The relative contributions of THC and CBD to migraine relief are not well-established.

THC has the stronger acute analgesic effects and directly activates CB1 receptors in pain-processing brain regions. The Cuttler app-based study found that higher THC concentrations correlated with greater migraine severity reduction, and that CBD content did not significantly predict effectiveness. This suggests that THC may be the more important component for acute migraine pain.

CBD has anti-inflammatory properties, modulates serotonergic transmission through 5-HT1A receptor agonism, and may influence CGRP signaling. These mechanisms are relevant to migraine prevention. CBD does not produce intoxication, making it more suitable for daily preventive use where cognitive clarity is needed.

A combination of THC and CBD may offer advantages for both acute and preventive use. Many patients report that balanced-ratio products provide effective relief with fewer side effects than high-THC products alone. The 1:1 THC:CBD ratio used in Sativex has shown benefit in neuropathic pain, and some headache specialists have extrapolated this approach to migraines.

Delivery Method Considerations

The delivery method matters more for migraines than for many other conditions, because the clinical scenario differs significantly between acute attacks and preventive use.

For acute attacks: Inhaled cannabis (vaporized flower or concentrates) provides onset within 2 to 5 minutes, which is fast enough to intervene during the early phase of an attack. Sublingual tinctures offer onset within 15 to 30 minutes, which is slower but still reasonable. Oral products (edibles, capsules) take 30 to 90 minutes, which is often too slow for acute migraine treatment. Additionally, migraine-associated nausea may impair oral absorption.

For prevention: Oral products provide the most consistent blood levels over time. A daily capsule or oil taken at a consistent time provides steady-state cannabinoid levels that could theoretically support endocannabinoid tone. Sublingual tinctures are also reasonable for twice-daily preventive dosing.

Nasal delivery: Some companies are developing intranasal cannabis products specifically for migraine. Nasal delivery offers rapid onset, bypasses the GI tract (avoiding the nausea problem), and can deliver precise doses. This is a promising route but commercial availability remains limited.

Medication Overuse Headache Concern

Medication overuse headache (MOH) is a well-recognized complication of frequent acute migraine treatment. Regular use of triptans, NSAIDs, or combination analgesics for more than 10 to 15 days per month can paradoxically increase headache frequency and severity. MOH affects an estimated 1 to 2 percent of the general population and is a major cause of chronic daily headache.

Whether cannabis can cause MOH is unknown. No study has specifically investigated this question. The Cuttler study found reduced effectiveness over sessions but not dose escalation, which is a different pattern than classic MOH. Some clinicians have expressed concern that daily cannabis use for headache could produce a rebound phenomenon, but this has not been documented in the literature.

Until this question is answered, it is prudent to avoid daily acute cannabis use for headaches. If cannabis is used acutely, limiting use to fewer than 10 days per month, the same guideline applied to triptans, is a reasonable precaution.

Triptans and Cannabis Interaction

Many migraine patients use triptans as their primary acute treatment. Whether combining triptans with cannabis is safe is a question that comes up frequently but has not been formally studied.

Both triptans and cannabis affect serotonergic neurotransmission. Triptans are serotonin 5-HT1B/1D agonists. THC indirectly modulates serotonin release, and CBD is a partial agonist at 5-HT1A receptors. The theoretical concern would be additive serotonergic effects, but both act on different serotonin receptor subtypes and through different mechanisms. The risk of serotonin syndrome from this combination appears low based on available evidence, though it has not been directly studied.

A more practical concern is additive sedation. Triptans commonly cause drowsiness, and THC amplifies this effect. Patients who combine both treatments should avoid driving or activities requiring alertness.

What Neurologists Say

The American Academy of Neurology (AAN) has not issued a formal guideline on cannabis for migraine. The American Headache Society has acknowledged the growing interest and the need for research but has not endorsed cannabis as a migraine treatment.

Individual neurologists and headache specialists range from cautiously supportive to skeptical. Those who are supportive generally frame cannabis as a reasonable option for patients who have failed multiple conventional treatments. Those who are skeptical point to the absence of randomized controlled trials and the difficulty of standardizing dosing.

Several headache specialists have noted that the patient data, while uncontrolled, shows a consistency and magnitude of effect that warrants formal investigation. Multiple clinical trials of cannabis for migraine are now underway or being planned, and the results will substantially clarify the evidence base.

Practical Framework for Migraine Patients

For migraine patients who have discussed cannabis with their neurologist and want to explore it as an option, the following framework provides a starting point.

For acute use, keep a vaporizer or sublingual tincture available for attacks. Start with a low dose of THC (2.5 to 5 mg inhaled, or 2.5 mg sublingual). Use at the first sign of an attack. Limit acute use to fewer than 10 days per month to reduce the risk of potential overuse patterns.

For preventive use, consider a daily oral product with a CBD-dominant or balanced ratio. Start with 10 to 25 mg CBD with 1 to 2.5 mg THC daily. Take at a consistent time, preferably in the evening. Allow 4 to 8 weeks to assess preventive efficacy, as this is consistent with the timeframe used for conventional preventive medications.

Track your attacks. Keep a migraine diary that includes attack frequency, severity, duration, cannabis use (dose, product, timing), and any other acute treatments used. This data is essential for determining whether cannabis is actually helping.

Do not abandon treatments that work. If triptans, CGRP inhibitors, or other medications provide reliable relief, do not discontinue them to try cannabis. The strongest evidence supports cannabis as an adjunct, not a replacement, for established migraine treatments.

The Bottom Line

The evidence for cannabis and migraines is stronger than for many conditions but still falls short of what is needed for confident clinical recommendations. The endocannabinoid deficiency hypothesis provides a compelling rationale. Patient data consistently shows frequency reductions comparable to established preventive medications. And the biological mechanisms are well-aligned with known migraine pathophysiology.

What is missing are the randomized controlled trials that would confirm these signals and establish dosing protocols. Those trials are coming. In the meantime, the evidence supports a cautious trial for migraine patients who have not found adequate relief from conventional treatments, under the guidance of a knowledgeable healthcare provider.

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before making any changes to your treatment plan.

The Bottom Line

Evidence review of cannabis for migraines covering endocannabinoid deficiency, patient data, acute vs preventive use, THC vs CBD, delivery methods, medication overuse, and triptan interaction. CED hypothesis: Russo 2004 — migraine/fibromyalgia/IBS share insufficient endocannabinoid tone; Sarchielli 2007 — reduced CSF anandamide in chronic migraine; ECS modulates serotonin, glutamate, CGRP transmission; CB1 dense in PAG/thalamus/trigeminal nucleus caudalis. Patient data: Rhyne 2016 Pharmacotherapy — 121 patients, frequency dropped 10.4 to 4.6 attacks/month (>50% reduction); Cuttler 2020 Journal of Pain — app data, 49.6% migraine severity reduction, higher THC = greater relief, CBD not predictive; Aviram/Samuelly 2021 Brain Sciences — 145 patients, sustained 3-year reductions. Acute vs preventive: inhaled = 2-5min onset for acute attacks; oral = steady-state for prevention; no RCT comparing protocols. THC vs CBD: THC stronger acute analgesic (CB1 pain regions); CBD anti-inflammatory/serotonergic for prevention; 1:1 ratio may optimize both. Delivery: inhaled for acute (nausea bypassed); oral for prevention; nasal in development. MOH concern: Cuttler found reduced effectiveness over sessions but no dose escalation; unknown if cannabis causes MOH; limit acute use <10 days/month. Triptan interaction: different 5-HT receptor subtypes, low serotonin syndrome risk; additive sedation main concern.